-
Registry Of Patients Treated With Systemic Mold-Active Triazoles
Scottsdale/Phoenix, AZ
The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive mold infection (IMI). Specifically, the study goals are to examine real world patient characteristics and treatment patterns, associated healthcare resource utilization, and outcomes associated with use of mold-active triazoles (MATs) to treat invasive fungal infections (IFIs).
-
A Study to Detect and Candida auris
Rochester, MN
The purpose of this study is to develop a test that can be used routinely to detect and identify Candida auris from surveillance skin swabs.
-
A Study to Evaluate Interferon-gamma in Antifungal Immunity
Rochester, MN
The purpose of this study is to evaluate the role of interferon-gamma (IFN-γ) in antifungal defense and its potential use in adjunctive immunotherapy. Solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients are at increased risk for invasive fungal infections. Mortality rates remain unacceptably high despite antifungal treatment. Novel therapeutic modalities are urgently needed. In this project, we propose to study the role of interferon-gamma (IFN-gamma) in antifungal defense and its potential use in adjunctive immunotherapy.
-
Safety And Efficacy Of PC945 (Opelconazole) In Combination With Other Antifungal Therapy For The Treatment Of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)
Jacksonville, FL
The purpose of this study is to assess the effectiveness of nebulized PC945 in combination with systemic antifungal therapy for the treatment of refractory Invasive Pulmonary Aspergillosis (IPA).
-
Study Of Rezafungin Compared To Standard Antimicrobial Regimen For Prevention Of Invasive Fungal Diseases In Adults Undergoing Allogeneic Blood And Marrow Transplantation (ReSPECT)
Rochester, MN
The primary objective of the United States Food and Drug Administration (FDA) for this study is to demonstrate non-inferiority in subjects who received an allogeneic BMT for subjects randomized to Rezafungin for Injection compared to subjects randomized to the standard antimicrobial regimen (SAR) for fungal-free survival at Day 90 (±7 days).
The primary objective of the European Medicines Agency (EMA) for this study is to demonstrate superiority in subjects who received an allogeneic BMT randomized to Rezafungin for Injection compared to subjects randomized to the SAR for fungal-free survival at Day 90 (±7 days).